

Date	Time PDT	Track	Presentation Title	Speaker
30-Aug	08:00 - 09:00 AM		â€˜HipSci' and the â€˜Stem cell hotel': innovative platforms for collaborative phenotyping	Davide Danovi, PhD Director of HipSci Cell Phenotyping Centre for Stem Cells and Regenerative Medicine, King's College London, United Kingdom
30-Aug	08:00 - 09:00 AM		Analyzing Stem Cell Populations using Flow Cytometry	Jolene Bradford, MLS(ASCP)CM, CCy Associate Director, Strategic Collaborations, Biosciences Division, Thermo Fisher Scientific
30-Aug	08:00 - 09:00 AM		Building embryonic lineages	Leo Kurian, PhD Independent Group Leader CECAD - Cluster of Excellence, Institute for Neurophysiology & Center for Molecular Medicine (CMMC), University of Cologne, Germany
30-Aug	08:00 - 09:00 AM		Challenge toward Clinical Trial for Spinal Cord Injury using iPS Cell	Hideyuki Okano, MD, PhD Dean, Professor, Department of Physiology, Keio University School of Medicine, Japan
30-Aug	08:00 - 09:00 AM		Delivery solutions for robust CRISPR-based genomic editing in stem cells for disease model generation	Nektaria Andronikou Staff Scientist, Cell Biology, Thermo Fisher Scientific
30-Aug	08:00 - 09:00 AM		Derivation of a Spectrum of Regional Motor Neuron Phenotypes for Hindbrain and Spinal Cord Regenerative Medicine	Randolph Ashton, PhD Assistant Professor, Department of Biomedical Engineering and Wisconsin Institute for Discovery- BIONATES, University of Wisconsin-Madison
30-Aug	08:00 - 09:00 AM		Directed differentiation of induced pluripotent stem cells to hepatic stellate cells	Pau Sancho Bru, PhD IDIBAPS Researcher, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Spain

30-Aug	08:00 - 09:00 AM		Disease modeling in pluripotent stem cell-derived cardiomyocytes	Chris Denning, PhD Professor in Stem Cell Biology, University of Nottingham, United Kingdom
30-Aug	08:00 - 09:00 AM		Elucidating the physiological function of cellular PrPC using human iPS cel	Vijay Chandrasekar, PhD Postdoctoral Fellow, University of Zurich, Switzerland
30-Aug	08:00 - 09:00 AM		Endoderm Progenitors in Health and Disease	Martin Pera, PhD Professor, Chair of Stem Cell Sciences, Program Leader, Stem Cells Australia, The University of Melbourne, Walter and Eliza Hall Institute of Medical Research, Florey Neuroscience and Mental
30-Aug	08:00 - 09:00 AM		Exploring new avenues for cataract treatment using human pluripotent stem cells	Michael O'Connor, PhD Director, Molecular Medicine Research Group, Western Sydney University, Australia, Senior Lecturer, School of Medicine, Western Sydney University, Australia Honorary Senior Lecturer, Save S
30-Aug	08:00 - 09:00 AM		First Allogeneic Mesenchymal Stromal Cell Product Approved in India for Buerger's Disease - An Unmet Medical Need	Anish Sen Majumbar, PhD CSO & Executive VP, Stempeutics Research, India
30-Aug	08:00 - 09:00 AM		From millions to billions to trillions - translating your cell discovery into a cell product	Nick Timmins, PhD Vice President, Technology and Director, BridGE at CCRM, Canada
30-Aug	08:00 - 09:00 AM		From urine to the study of metabolic disease - A patient-driven strategy to decipher PCSK9 roles and functions.	Karim Si-Tayeb, PhD Young Investigator, l'institut du thorax INSERM, France
30-Aug	08:00 - 09:00 AM		Human pluripotent stem cells for the study of enteric neuropathies	Faranak Fattahi, PhD PhD candidate, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medicine

30-Aug	08:00 - 09:00 AM		Human PSC-based disease modeling to study X-linked Dystonia-Parkinsonism	William Hendriks Instructor in Neurology, Harvard Medical School
30-Aug	08:00 - 09:00 AM		Human umbilical cord mesenchymal cells and the treatment of bronchopulmonary dysplasia	Willie Lin, PhD Chief Executive Officer, Meridigen Biotech Co., Ltd., Taiwan
30-Aug	08:00 - 09:00 AM		Immunomodulation and immunogenicity of human MSC-like cells : What did we learn from in vitro and in vivo studies ?	Hans-Dieter Volk, MD Chairman, Institute for Med. Immunology & Berlin-Brandenburg Center for Regenerative Therapies (BCRT) & Dept. Immunology, Labor Berlin Vivantes, Charit� GmbH Charit�-Universit�tsmedizin, Berl
30-Aug	08:00 - 09:00 AM		Improved differentiation of human pluripotent stem cell-derived neurons through reduction of progenitor proliferation: impact on downstream applications	David Thomas Kuninger, PhD Director and Group Leader, Thermo Fisher Scientific
30-Aug	08:00 - 09:00 AM		iPSC Generation and Validation: Ensuring the best materials for downstream applications iPSC Generation and Validation: Ensuring the best materials for downstream applications	Rene Quintanilla Jr. R&D Scientist, Cell Biology, Thermo Fisher Scientific
30-Aug	08:00 - 09:00 AM		Optimizing retinal cell differentiation of human pluripotent stem cells for large-scale disease modeling.	Alice P�bay, PhD Associate Professor, ARC Future Fellow, Head, Neuroregeneration Research Unit, Centre for Eye Research Australia, University of Melbourne

30-Aug	08:00 - 09:00 AM		Precise generation of desired human cell-types from embryonic stem cells	Lay Teng Ang, PhD Senior Research Fellow, Genome Institute of Singapore, Singapore
30-Aug	08:00 - 09:00 AM		Regulation of Autologous Cell Clinical Interventions	Bernie Tuch, PhD Director, NSW Stem Cell Network, Australia
30-Aug	08:00 - 09:00 AM		Stem Cells for Regeneration and Rescue	Jeanne Loring Professor of Developmental Neurobiology Director of the Center for Regenerative Medicine, The Scripps Research Institute
30-Aug	08:00 - 09:00 AM		Techniques and recommendations for colony selection and passage of iPSC	Chad MacArthur R&D Scientist, Thermo Fisher Scientific
30-Aug	08:00 - 09:00 AM		The matrix equation - solving for the best pluripotent stem cell culture goals	Rhonda Newman, PhD Senior Staff Scientist, Cell Biology, Thermo Fisher Scientific
30-Aug	08:00 - 09:00 AM		Tissue engineering with human pluripotent stem cells	Nuria Montserrat, PhD Junior Group Leader, Pluripotent Stem Cells and Activation of Endogenous Tissue Programs for Organ Regeneration, The Institute for Bioengineering of Catalonia (IBEC), Spain
30-Aug	08:00 - 09:00 AM		Transitioning to the clinic from proof of concept research: Challenges associated with converting research materials and methods to a clinical grade product	Ben Fryer, PhD Team Leader, Processing/Manufacturing, Heart Regeneration Program, University of Washington School of Medicine, United States
30-Aug	08:00 - 09:00 AM		Translating Pluripotent Stem Cell Therapies For Focal Brain Disorders	Dustin Wakeman, PhD Senior Research Scientist, Regenerative Medicine RxGen, Inc.

30-Aug	08:00 - 09:00 AM	Transplanted human stem cell-derived interneuron precursors mitigate mouse bladder dysfunction and central neuropathic pain after spinal cord injury	Cory Nicholas, PhD Co-Founder and Chief Scientific Officer, Neurona Therapeutics, Assistant Professor, Adjunct, University of California, San Francisco, United States
30-Aug	08:00 - 09:00 AM	Use of Stem Cell models to assess Genetic Change Underlying Neurodevelopmental Disorders	Lachlan Jolly, PhD ARC DECRA Fellow, Neurogenetics Research Program, School of Medicine, Faculty of Health Sciences, The University of Adelaide, Australia
16-Nov	04:00 - 05:00 PM	Evolving your media system for modern stem cell applications	Rhonda Newman, PhD Senior Staff Scientist, Cell Biology, Thermo Fisher Scientific
16-Nov	06:00 - 07:00 PM	Optimization of your PSCs workflow	Jing He, PhD Technical Application Scientist, Cell Biology, Life Sciences Solutions, Thermo Fisher Scientific
17-Nov	03:00 - 04:00 AM	Genetic variability of ps-iPSC and related blood and fibroblasts - somatic mutations	KEYNOTE: Silke Rickert-Sperling, PhD Professor, Experimental and Clinical Research Center, Charit�-Universit�tsmedizin Berlin, Germany
17-Nov	05:00 - 06:00 AM	Partnering to advance regenerative medicine and cellular therapies	Michael Werner Partner, Holland & Knight Morrie Ruffin, PhD Managing Director, Alliance for Regenerative Medicine
17-Nov	07:00 - 08:00 AM	Using patient-derived iPSCs to model and treat inherited retinal degenerative blindness	KEYNOTE: Budd Tucker, PhD Stephen A. Wynn Associate Professor of Regenerative Ophthalmology, Director Steven W. DeZii Translational Vision Research Facility, Wynn Institute for Vision Research, Department of Ophthal

17- Nov	09:00 - 10:00 AM		From bench to BLA - a review of common regulatory questions	Joyce Frey-Vasconcells, PhD Regulatory Consultant, Frey-Vasconcells Consulting, LLC Michael Mendicino, PhD Owner, Chief Consultant & Advisor, Hybrid Concepts International Kelli Tanzella, PhD Sr. Director Global Regulatory Affairs, Clinical, & Compliance for Life Sciences Solution Group (LSG), Thermo Fisher Scientific
17- Nov	01:00 - 02:00 PM		Initiatives to advance stem cell science and medicine at California's \$3 billion stem cell agency	Stephen Lin, PhD Senior Science Officer, Strategic Infrastructure, California Institute for Regenerative Medicine
17- Nov	03:00 - 04:00 PM		Molecular elucidation and engineering of stem cell fate decisions	David Schaffer, PhD Professor of Chemical and Biomolecular Engineering, Department of Bioengineering, Director of the Berkeley Stem Cell Center, University of California at Berkeley
21- Feb	11:00 - 12:00 PM		Genome Engineering to Introduce a Fluorescent Reporter into Human Pluripotent Stem Cells to Study Cardiac Disease	Lise Munsie, PhD Development Scientist, CCRM
1- May	08:00 - 09:00 AM		Improved differentiation of stem cell-derived neurons and downstream applications through the reduction of progenitor proliferation with CultureOne™,ç Supplement	David Thomas Kuninger, PhD Director and Group Leader, Thermo Fisher Scientific
1- May	08:00 - 09:00 AM		Using iPSCs and Genome Engineering to Build Disease Models	David Piper, PhD Director of R&D, Cell Biology, Thermo Fisher Scientific

8-Jun	12:00 - 01:00 PM		Improved CRISPR Cas9 Editing of Pluripotent Stem Cells Utilizing the Latest Technologies from Thermo Fisher Scientific	Rhonda Newman, PhD Senior Staff Scientist, Cell Biology, Thermo Fisher Scientific
-------	---------------------------	--	--	--